RIGL Rigel Pharmaceuticals Inc.

2.22
+0.01  (+0%)
Previous Close 2.21
Open 2.21
Price To Book 3.9
Market Cap 371,169,370
Shares 167,193,410
Volume 2,147,003
Short Ratio
Av. Daily Volume 1,507,572

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data released April 3, 2018. Primary endpoint not met.
Fostamatinib
IgA nephropathy
Phase 2 trial did not meet endpoints
R348
Chronic dry eye disease - as a result of patients with acute or chronic graft vs. host disease (GvHD)
Approved April 17, 2018.
Tavalissetm (Fostamatinib)
Immune Thrombocytopenic Purpura (ITP)
Phase 3 data due early 2021.
Fostamatinib
Autoimmune hemolytic anemia (AIHA)
Phase 1 trial to be completed mid-2019.
R835
Autoimmune and inflammatory diseases

Latest News

  1. Here’s What Hedge Funds Think About Rigel Pharmaceuticals, Inc. (RIGL)
  2. Rigel to Present Two Posters Highlighting Fostamatinib at the 24ᵗʰ Congress of the European Hematology Association (EHA)
  3. Is Rigel Pharmaceuticals a Buy?
  4. Rigel Pharmaceuticals Sees Hammer Chart Pattern: Time to Buy?
  5. Edited Transcript of RIGL earnings conference call or presentation 7-May-19 8:30pm GMT
  6. Rigel to Present at Jefferies 2019 Healthcare Conference
  7. Rigel Initiates Enrollment in Pivotal Blood Disorder Study
  8. Rigel Enrolls First Patient in Phase 3 Clinical Trial of Fostamatinib Disodium Hexahydrate in Warm Autoimmune Hemolytic Anemia
  9. Rigel Pharmaceuticals Inc (RIGL) Q1 2019 Earnings Call Transcript
  10. Rigel Pharmaceuticals (RIGL) Reports Q1 Loss, Tops Revenue Estimates
  11. Rigel: 1Q Earnings Snapshot
  12. Rigel Announces First Quarter 2019 Financial Results and Provides Company Update
  13. Rigel Announces Conference Call and Webcast to Report First Quarter 2019 Financial Results and Company Update
  14. If You Had Bought Rigel Pharmaceuticals (NASDAQ:RIGL) Stock A Year Ago, You'd Be Sitting On A 40% Loss, Today
  15. Here's Why Rigel Pharmaceuticals Gained 17.3% in March
  16. Rigel Welcomes Jane Wasman to Board of Directors
  17. Is Rigel Pharmaceuticals, Inc.’s (NASDAQ:RIGL) CEO Overpaid Relative To Its Peers?
  18. Edited Transcript of RIGL earnings conference call or presentation 28-Feb-19 10:00pm GMT
  19. Rigel Pharmaceuticals (RIGL) Q4 2018 Earnings Conference Call Transcript
  20. Rigel Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Company Update